<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172558</url>
  </required_header>
  <id_info>
    <org_study_id>IDIRB2017122601-34</org_study_id>
    <nct_id>NCT04172558</nct_id>
  </id_info>
  <brief_title>Intracavernous Injection of Botox 100 U for Treatment of PDE5Is Inconvenient Patients With ED</brief_title>
  <official_title>Intracavernous Injection of Onabotulinumtoxin-A 100 U For Treatment of Phosphodiesterase Type 5 Inhibitors-Inconvenient Patients With Erectile Dysfunction: A Randamized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a new emerging concept that Botulinum Toxin Type A may have a potential role in
      treatment of erectile dysfunction with a longer duration of action. So, the investigators
      opted to perform this study to compare ICI of Botulinum Toxin Type A versus Trimix for
      treatment of ED.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Direct Intracavernosal injections of vasoactive agents to treat erectile
      dysfunction were first described in 1982 using papaverine. Later on many agents have been
      introduced for ICI. one of most newly introduced ICI agents for treatment of ED is Botulinum
      Toxin Type A.

      Purpose: The aim of this study will to compare the safety, efficacy, tolerability and adverse
      events s of ICI of BTX-A 100 unit in comparison with ICI Trimix in the treatment of Erectile
      Dysfunction for PDE5Is non-responders.

      Design, Settings, and Participants: This study will be conducted on 124 patients at minimum,
      complain of erectile dysfunction not responding to different PDE5Is therapy presenting to
      Urology department and outpatient clinic at Banha University Hospital.

      patients will be randomized into 2 equal groups: The treatment group A: will receive a single
      ICI of BTX-A 100 units . The treatment group B: will receive on-demand ICI of Trimix .

      Assessment for all groups will be done by Sexual Health Inventory for men (SHIM), Sexual
      Encounter Profile questions 2 and 3 (SEP 2 &amp; SEP 3), and the global assessment question (GAQ)
      based on pre-treatment, 2 weeks, 3 months and every 3 months after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Index of Erectile Function (IIEF)</measure>
    <time_frame>baseline, 2 weeks post treatment then every 3 months post treatment</time_frame>
    <description>Changes in the Erectile Function (EF) domain score of the International Index of change of Erectile Function measured by (IIEF) between treatment periods and baseline in the 2 study arms. It ranges between 0 to 25</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dopller study</measure>
    <time_frame>baseline, 2 weeks post treatment then every 3 months post treatment</time_frame>
    <description>measurement of Cavernosal artery peak systolic and end diastolic velocities before and after ICI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Erection hardness score [ Time Frame: 2 weeks ] [ Designated as safety issue: No ] Clinical assessment of the Erection hardness score by the investigators in both Erection hardness score</measure>
    <time_frame>baseline, 2 weeks post treatment then every 3 months post treatment</time_frame>
    <description>Erection hardness score which is ranged 0 to 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sexual Encounter Profile 2&amp;3</measure>
    <time_frame>baseline, 2 weeks post treatment then every 3 months post treatment</time_frame>
    <description>Assessment of SEP before and after ICI. patient answer ' Yes' or 'No'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment Questionnaire</measure>
    <time_frame>baseline, 2 weeks post treatment then every 3 months post treatment</time_frame>
    <description>Global Assessment Questionnaire with Yes/No response</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>BTX100 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ICI of Botox 100 U</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trimix group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ICI of Trimix</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OnabotulinumtoxinA</intervention_name>
    <description>a single ICI of BTX-A 100 units one day after the penile Doppler/trimix test.</description>
    <arm_group_label>BTX100 group</arm_group_label>
    <other_name>Grroup 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimix</intervention_name>
    <description>on demand ICI of Trimix</description>
    <arm_group_label>Trimix group</arm_group_label>
    <other_name>Group 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age more than 40 years with ED not responding to PDE5Is, non compliant or
             contraindicated to PDE5Is. A &quot;No&quot; response on Sexual encounter profile questions (SEP
             2 &amp; 3)

        Exclusion Criteria:

          -  psychiatric condition Any presence of penile anatomical abnormalities (e.g. penile
             fibrosis) that would significantly impair erectile function.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waleed El-Shaer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Banha Univesity hosptals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Waleed El-Shaer, MD</last_name>
    <phone>01015767331</phone>
    <email>waleed_elshaer@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banha University Hospitals</name>
      <address>
        <city>Banha</city>
        <state>Kalubiaya</state>
        <zip>13518</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waleed El-Shaer</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>March 29, 2020</last_update_submitted>
  <last_update_submitted_qc>March 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Waleed El-Shaer, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Botulimium Toxin</keyword>
  <keyword>Eractile Dysfunction</keyword>
  <keyword>ICI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

